Huhn Stephen L.
Known title: CMO & Sr VP, Clinical Dev.CIK: 0001863904
Associated companies
Transaction History
| CTNM | ▲ Buy | Option Exercise | 12,800 | $13K | 8/13/2024 | View on chart |
| CTNM | ▲ Buy | Option Exercise | 12,800 | $13K | 8/13/2024 | View on chart |
We use analytics to understand how market-wall is used. No personal data is sold.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 25, 2026
CTNM Depressed After Phase 2 Miss
Contineum Therapeutics recently announced that its depression drug, developed with Johnson & Johnson, failed to meet its primary goal in a Phase 2 trial. This clinical setback is a significant event for the company, as it raises questions about the future development timeline and potential commercialization of the asset. The stock is currently trading near its 52-week low, reflecting the market's reaction to this negative data.
CTNM Depressed After Phase 2 Miss. Contineum Therapeutics recently announced that its depression drug, developed with Johnson & Johnson, failed to meet its primary goal in a Phase 2 trial. This clinical setback is a significant event for the company, as it raises questions about the future development timeline and potential commercialization of the asset. The stock is currently trading near its 52-week low, reflecting the market's reaction to this negative data.